The treatment and clinical follow-up outcome in Iranian patients with tetrahydrobiopterin deficiency

Abstract

Objectives This study aimed to evaluate the biochemical factors, genetic mutations, outcome of treatment, and clinical follow-up data of Iranian patients with tetrahydrobiopterin (BH4) deficiency from April/2016 to March/2020. Methods Forty-seven BH4 deficiency patients were included in the study and underwent biochemical and genetic analyses. The clinical outcomes of the patients were evaluated after long-term treatment. Results Out of the 47 (25 females and 22 males) BH4 deficiency patients enrolled in the study, 23 were Dihydropteridine reductase (DHPR) deficient patients, 23 were 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficient patients, and one was GTP-Cyclohydrolase 1 deficiency (GTPCH-1) patient. No clinical symptoms were observed in 10 of the DHPR deficient patients (before and after the treatment). Also, most patients diagnosed at an early age had a proper response to the treatment. However, drug therapy did not improve clinical symptoms in three of the patients diagnosed at the age of over 10 years. Also, 16 PTPS deficiency patients who were detected within 6 months and received treatment no clinical symptoms were presented. One of the patients was detected with GTPCH deficiency. Despite being treated with BH4, this patient suffered from a seizure, movement disorder, mental retardation, speech difficulty, and hypotonia. Conclusions The study results showed that neonatal screening should be carried out in all patients with hyperphenylalaninemia because early diagnosis and treatment can reduce symptoms and prevent neurological impairments. Although the BH4 deficiency outcomes are highly variable, early diagnosis and treatment in the first months of life are crucial for good outcomes.

Biochemical and molecular features of tetrahydrobiopterin deficiency in Fujian Province, southeastern China

“…Newborn screening (NBS) programs for HPA have been implemented in many countries, resulting in significant improvements in BH4D early diagnosis and treatment ( Shintaku and Ohwada, 2013 ; Khani et al, 2021 ). BH4D incidence is approximately 1%–3% among patients with HPA worldwide ( Dhondt and Hayte, 2002 ; de Baulny et al, 2007 ; Dhondt, 2010 ; Wang et al, 2021 ).…”